Scan QR
What is Keytruda?
Keytruda (pembrolizumab) is a type of immunotherapy that is given by intravenous (into a vein) infusion over 30 minutes to treat many different types of cancer such as melanoma, lung cancer, and some lymphomas (see below for the full list of cancers Keytruda is approved for). It may be used alone or in combination with other medicines, including chemotherapy.
Keytruda works by binding to and blocking the interaction of the PD-1 (programmed death receptor-1) receptor with other proteins including PD-L1 and PD-L2. An upregulation of the PD-1 receptors occurs in some cancers and signaling through this pathway prevents the T-cells in our immune system from finding and attacking cancer cells. Anim...
Scan QR
What is Keytruda?
Keytruda (pembrolizumab) is a type of immunotherapy that is given by intravenous (into a vein) infusion over 30 minutes to treat many different types of cancer such as melanoma, lung cancer, and some lymphomas (see below for the full list of cancers Keytruda is approved for). It may be used alone or in combination with other medicines, including chemotherapy.
Keytruda works by binding to and blocking the interaction of the PD-1 (programmed death receptor-1) receptor with other proteins including PD-L1 and PD-L2. An upregulation of the PD-1 receptors occurs in some cancers and signaling through this pathway prevents the T-cells in our immune system from finding and attacking cancer cells. Animal studies have found that blocking PD-1 receptors helps the immune system to slow or stop the growth and spread of cancer cells in the body. Keytruda belongs to the class of monoclonal antibodies called PD-1 blocking antibodies.
Keytruda may be used to treat:
* skin cancer (melanoma, Merkel cell carcinoma, squamous cell carcinoma)
* lung cancer, Non-Small Cell Lung Cancer (NSCLC)
* head and neck cancer
* classical Hodgkin lymphoma
* primary mediastinal large B-cell lymphoma
* cancer of the kidney, bladder, and urinary tract
* colorectal cancer
* liver cancer
* triple-negative breast cancer
* cancer of the cervix or uterus
* microsatellite instability-high or mismatch repair deficient solid tumors
* tumor mutational burden-high (TMB-H) cancer
* advanced stomach or esophageal cancer
* locally advanced unresectable or metastatic biliary tract cancer (BTC)
* locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, or
* a type of cancer that laboratory testing proves to have certain specific DNA mutations.
For more information
Email : sales@lexionpham.com
Website : www.lexionpham.com
